REVANCE THERAPEUTICS INC (RVNC)
US7613301099 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 132.61M | 137.33M | 109.00M | 110.60M | 333.60M | |||
| Marketable Securities | 144.46M | 116.59M | 231.70M | 114.40M | 102.90M | |||
| Receivables | 29.89M | 27.68M | 11.30M | 3.30M | 1.80M | |||
| Inventories | 50.28M | 45.58M | 18.30M | 10.20M | 5.90M | |||
| Other Current Assets | 12.45M | 11.70M | 4.40M | 7.50M | 5.80M | |||
| Total Current Assets | 369.69M | 338.87M | 374.70M | 246.10M | 450.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 87.75M | 90.21M | 67.80M | 69.00M | 47.10M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | N/A | 0.00 | 77.20M | 147.00M | 147.00M | |||
| Intangibles | 8.72M | 9.81M | 27.00M | 55.30M | 71.30M | |||
| Other Non-Current Assets | 41.96M | 39.57M | 35.20M | 13.70M | 4.80M | |||
| Total Non-Current Assets | 138.43M | 139.59M | 207.20M | 285.10M | 270.20M | |||
| TOTAL ASSETS | 508.12M | 478.45M | 581.90M | 531.20M | 720.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 5.00M | 5.15M | 700.00K | N/A | N/A | |||
| Accrued Expenses | 46.20M | 56.34M | 57.00M | 42.90M | 35.90M | |||
| Accounts Payable | 5.28M | 13.81M | 4.50M | 10.60M | 12.70M | |||
| Other Current Liabilities | 12.43M | 13.92M | 13.40M | 13.80M | 12.40M | |||
| Total Current Liabilities | 68.90M | 89.22M | 75.70M | 67.30M | 61.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 424.84M | 426.60M | 379.40M | 280.60M | 180.50M | |||
| Other Non-Current Liabilities | 113.05M | 114.24M | 114.20M | 114.80M | 104.40M | |||
| Total Non-Current Liabilities | 537.89M | 540.83M | 493.60M | 395.40M | 284.90M | |||
| TOTAL LIABILITIES | 606.79M | 630.06M | 569.30M | 462.70M | 345.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.13B | -2.08B | -1.75B | -1.40B | -1.13B | |||
| Additional Paid In Capital | 2.03B | 1.93B | 1.77B | 1.47B | 1.50B | |||
| Common Shares | 104.00K | 88.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -25.00K | 14.00K | -400.00K | 0.00 | 0.00 | |||
| Shares Outstanding | 104.41M | 87.96M | 82.40M | 71.60M | 69.20M | |||
| Tangible Book Value per Share | -1.03 | -1.83 | -1.11 | -1.87 | 2.25 | |||
| Total Shareholders' Equity | -98.67M | -151.60M | 12.60M | 68.50M | 374.30M | |||
| TOTAL LIABILITIES AND EQUITY | 508.12M | 478.45M | 581.90M | 531.20M | 720.20M | |||
| Statistics | ||||||||
| Debt/Equity | -4.31 | -2.81 | 30.11 | 4.10 | 0.48 | |||
| Current Ratio | 5.37 | 3.80 | 4.95 | 3.66 | 7.38 | |||
| Return On Assets (ROA) | -62.46% | -67.72% | -61.25% | -52.96% | -39.17% | |||
| Return On Equity (ROE) | N/A | N/A | -2828.57% | -410.66% | -75.37% | |||
All data in USD